98%
921
2 minutes
20
Introduction: To understand neuromyelitis optica spectrum disorders (NMOSDs) better we need to study them in different populations. This prospective study was conducted to characterize clinical, serological, radiological, and therapeutic profile of NMOSDs in a North Indian population.
Materials And Methods: This study included 81 patients with NMOSDs. All patients underwent detailed history and examinations and were followed at 3 monthly intervals. They were evaluated using standard investigations including gadolinium-enhanced magnetic resonance imaging (MRI) of the brain and spine with thin section optic nerve cuts and treated as per the standard guidelines. Data were recorded meticulously.
Results: The mean age was 33.7 ± 13.4 years. The mean age at disease onset was 31.2 ± 13.5 years. Female-to-male ratio was 1.9:1. About 32.1% of patients presented with optic neuritis (ON), 56.8% with transverse myelitis (TM), and 11.1% with both ON and TM. The mean time from disease onset to diagnosis was 16.17 ± 23.09 months. Muscle atrophy, Lhermitte symptom, and tonic spasms were common. Foster-Kennedy syndrome-like presentation was seen in 8.6%. NMO antibodies were positive in 41 patients. MRI revealed involvement of <4 vertebral segments in 16.4% of patients with TM. Patients were managed as per standard guidelines. The mean follow-up duration was 15.3 ± 6 months. Approximately 88.9% had good functional outcome.
Conclusion: NMOSDs are a common cause of demyelinating illnesses in Northern India. The response to treatment is excellent and most patients recover without residual disability.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4103/0028-3886.355118 | DOI Listing |
Neurol Neuroimmunol Neuroinflamm
November 2025
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Background And Objectives: Myelitis is a relatively common clinical entity for neurologists, with diverse underlying causes. The aim of this study was to describe the incidence of myelitis, its causes, clinical presentation, and factors predicting functional outcomes and relapses.
Methods: Using the Swedish National Patient Registry, we identified all adult patients in Stockholm County between 2008 and 2018 using International Classification of Diseases, 10th Edition (ICD-10) codes likely to include myelitis.
Mult Scler
September 2025
Department of Neurology, Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, MA, USA.
Background: Financial toxicity (FT) and the social determinants of health (SDOH) remain underexplored in neuromyelitis optica spectrum disorder (NMOSD).
Objective: To characterize FT in NMOSD and examine sociodemographic and clinical features.
Methods: We conducted a convenience-sampled, cross-sectional, anonymous survey (08/2024-03/2025) of 124 U.
Neurol Neurochir Pol
September 2025
Institute of Medical Sciences, Collegium Medicum, University of Zielona Góra, Zielona Góra, Poland.
Clin Neurol Neurosurg
October 2025
Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
We present the case of a 54-year-old patient treated with cemiplimab, an immune checkpoint inhibitor (ICI), for multiple basal cell carcinomas in the context of Gorlin Goltz syndrome. Gorlin Goltz syndrome is an autosomal dominant multisystem disorder characterized, among other features, by multiple early-onset basal cell carcinomas (BCCs). After receiving Cemiplimab, she developed aquaporin-4 antibody (AQP4-Ab) positive neuromyelitis optica spectrum disorder (NMOSD).
View Article and Find Full Text PDFMult Scler Relat Disord
September 2025
Neurologist-Neuroimmunologist. Associate Professor of Neurology, Neuroscience Department, Division of Neurology, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia. Electronic address:
Background: Headache is a common but underrecognized symptom in optic neuritis (ON), with potential implications for diagnosis and management.
Objective: To assess the clinical and radiological factors associated with headache in patients with acute ON.
Methods: We conducted a retrospective case-control study in a tertiary hospital in Bogotá, Colombia (2022-2024).